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Background: Chronic musculoskeletal (MS) pain is common in patients with chronic kidney disease (CKD)
undergoing haemodialysis. However, epidemiological data for chronic MS pain and factors associated with chronic
MS pain in patients with early- or late-stage CKD who are not undergoing dialysis are limited.
Method: A cross-sectional study to evaluate the prevalence of chronic MS pain and factors associated with chronic
MS pain in patients with early- and late-stage CKD who were not undergoing dialysis, was conducted. In addition,
the distribution of pain severity among patients with different stages of CKD was evaluated.
Results: Of the 456 CKD patients studied, 53.3% (n = 243/456) had chronic MS pain. Chronic MS pain was
independently and significantly associated with hyperuricemia as co-morbidity, as well as with the calcium ×
phosphate product levels. In CKD patients with hyperuricemia, chronic MS pain showed a negative, independent
significant association with diabetes mellitus as a co-morbidity (odds ratio: 0.413, p = 0.020). However, in the CKD
patients without hyperuricemia as a co-morbidity, chronic MS pain showed an independent significant association
with the calcium × phosphate product levels (odds ratio: 1.093, p = 0.027). Furthermore, stage-5 CKD patients
seemed to experience more severe chronic MS pain than patients with other stages of CKD.
Conclusion: Chronic MS pain is common in CKD patients. Chronic MS pain was independently and significantly
associated with hyperuricemia as co-morbidity, and with the calcium × phosphate product levels in early- and
late-stage CKD patients who were not on dialysis.
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The worldwide prevalence of chronic kidney disease
(CKD) continues to increase [1]. CKD patients develop
many complications, which lead to a high risk of co-
morbidities and mortality [2-4].Therefore, two issues are
important for healthcare professionals caring for CKD
patients: (1) prolonging the life span and (2) improved
quality of life of patients.
CKD patients have a poor quality of life [5]. This may
be attributed to the underlying disease or to the compli-
cations associated to CKD. The Dialysis Outcomes and* Correspondence: maiszuwu@gmail.com
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reproduction in any medium, provided the orPractice Patterns Study (DOPPS), a large, international,
observational study, demonstrated that quality-of-life
indicators from SF-36 were associated with differential
survival and morbidity [6]. Body pain is one of the most
important qualitative parameters for evaluating patients’
quality of life [7]. To improve quality of care provided to
CKD patients, it is important to understand and relieve
body pain.
It has been reported that 82% of CKD patients undergo-
ing dialysis had chronic pain, [8] and 35-70% of patients
had moderate to severe chronic pain [9]. Chronic pain is
common in CKD patients [10], especially in patients with
end-stage renal disease (ESRD) [11]. Musculoskeletal (MS)
pain is the most common symptom of chronic pain
syndromes in ESRD patients [8]. Few studies have focused
on chronic pain in early-stage CKD patients.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tors associated with chronic MS pain in CKD patients
undergoing dialysis, the epidemiologic data for factors
associated with chronic MS pain in early- and late-stage
CKD patients who are not on dialysis, are limited. In
addition, information about the prevalence of non-
steroidal anti-inflammatory drugs (NSAID) or Chinese
herbs used for pain relief in CKD patients is also limited.
The aims of this study were to determine the prevalence
of chronic MS pain in CKD patients and to identify the
factors associated with chronic MS pain.
Methods
Patients
Pre-dialysis CKD patients who visited an outpatient
clinic at the Nephrology Department of Chang Gung
Memorial Hospital at Keelung, from March 2006 to July
2007, were recruited for the study. Patients satisfying the
following criteria were included in this study consecu-
tively: between 18 to 80 years old, and with no spontan-
eous improvement or progression of renal disease in the
3 months prior to the start of the study. Patients with
acute illness requiring hospital admission in the past
3 months, cancer without remission, or who were
unwilling to participate in the trial were excluded from
the study. CKD was defined as the presence of persistent
proteinuria, or a decreased estimated glomerular filtrationFigure 1 Flow chart indicates patient enrolment.rate (eGFR) of <90 mL/min per 1.73 m2 [determined by
the CKD Epidemiology Collaboration (CKD-EPI) creatin-
ine equation], in two separate measurements within an
interval of 3 months [12]. In accordance with the National
Kidney Foundation/Dialysis Outcomes Quality Initiative
(NKF/DOQI) classification system, these patients were
classified into stages 1, 2, 3, 4, or 5 for descriptive
purposes. A total of 456 patients who provided informed
consent were enrolled into the study (Figure 1). This study
complies with the Declaration of Helsinki and was
approved by the Ethics Committee of the Institutional
Review Board at Chang Gung Memorial Hospital. The
study was conducted at the CKD centre of the Chang
Gung Memorial Hospital, Keelung, Taiwan.
Study design
All eligible patients were carefully interviewed to identify
primary disease and current medications. At the time of
the visit, we also checked the patients’ blood pressure
and performed laboratory tests. Chronic MS pain was
evaluated by the Community Oriented Program for the
Control of Rheumatic Diseases (COPCORD) question-
naire [13]. For patients with MS pain, pain was assessed
using a visual analogue scale (VAS), with a range of
0 mm (no pain) to 100 mm (very painful), after which
the patients were examined by a rheumatologist to
confirm the information and characterize MS pain
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other analyses, chronic MS pain was defined as non-
traumatic MS pain for a VAS score of >1 for more than
3 months [8]. Pain severity categories were defined in
this study as follows: VAS pain score of 30 mm or less,
mild pain; VAS pain score of 31 mm to 69 mm, moder-
ate pain; and VAS pain score of 70 mm or more, severe
pain. This categorization is based, in part, on the find-
ings of Collins et al. [14].
Basic demographic data were collected, including
information on age, gender, nutrition status (body mass
index [BMI] and waist circumference), history of smok-
ing, alcohol and betel nut consumption, current use
of NSAIDs or Chinese herbal medicines, and the pres-
ence of diabetes, hypertension, coronary artery disease
(CAD), peripheral arterial disease (PAD), congestive
heart failure (CHF), stroke, hyperuricemia, systemic
lupus erythematosus (SLE), urolithiasis, polycystic kid-
ney disease (PKD), rheumatoid arthritis (RA), spondylar-
thropathies, spine osteoarthritis (OA), and back pain.
Current use of diuretics or allopurinol was also col-
lected. Baseline haematological and biochemical data of
these patients were also collected. Smoking was defined
as the consumption of more than 10 cigarettes per day
for at least one year. Alcohol use was defined as daily
consumption of more than 80 mg of alcohol/day for
more than one year. Current use of NSAIDs was defined
by self-reported use of ibuprofen, naproxen, sulindac,
piroxicam, indomethacin, tolmetin, or diclofenac (with
brand names and combination formulas identified) daily
or nearly every day, for the last 30 days. Current use of
Chinese herbs was defined by self-reported use of any
Chinese herb daily or nearly every day, for the last
30 days. Diabetes mellitus was defined as a fasting glu-
cose level ≥126 mg/dL or use of any hypoglycaemic
medication. Hypertension was considered to be present
if the patient was on antihypertensive medicine, or if
blood pressure was >140/90 mm Hg. The presence of
CAD was confirmed by coronary angiography, and CHF
was diagnosed on the basis of the Framingham criteria
for heart failure [15]. PAD was defined based on either
the results of peripheral Doppler analysis, or a history of
amputation. Stroke was diagnosed by clinical symptoms
and the results of imaging studies. Hyperuricemia was
considered if the patient was on medicine for uric acid
control, or if blood uric acid level was >8.0 mg/dL. SLE
was defined as per the eleven criteria by the American
Rheumatism Association. The presence of urolithiasis
was defined by kidney echo report or previous history of
renal stone removal. The presence of PKD was defined
by kidney echo report. The presence of RA was defined
by the 2010 ACR/EULAR Rheumatoid Arthritis Classifi-
cation Criteria [16]. The presence of spondylarthropathy
was defined by the European Spondylarthropathy StudyGroup criteria for spondylarthropathy [17]. Spine OA
was defined by clinical history, findings on physical
examination, and radiographic findings suggested by
rheumatologists.
Laboratory measurements
Full laboratory profiles were obtained. The laboratory
parameters included levels of blood urea nitrogen, serum
creatinine (Scr), haemoglobin, albumin, calcium (Ca),
phosphate (P), intact parathyroid hormone (iPTH), total
cholesterol, triglycerides, uric acid, and high-sensitivity
C-reactive protein (hs-CRP). Serum creatinine levels
were assessed by spectrophotometric analysis using a
modified kinetic Jaffe reaction.
Statistical analysis
Descriptive statistics were expressed as means with stand-
ard deviation or percentage frequency, as appropriate.
All variables were tested for normal distribution by a
Kolmogorov-Smirnov test. The Student’s t-test or Mann–
Whitney U test was applied to compare means of continu-
ous variables. Categorical data were tested using the
chi-square test. Binary logistic regression was appropri-
ately used to test the factors associated with chronic MS
pain. To identify independent associations, stepwise multi-
variate regression analysis was used, and variables includ-
ing age, gender, and p < 0.05 in the univariate analysis
were selected. All analyses were performed by using the
commercially available statistics software, SPSS version
15.0 for Windows.
Results
Characteristics of the study population
Mean age of the patients was 63.3 ± 14.1 years and
42.5% (n = 194/456) of patients were male. The NSAID
and Chinese herb use by CKD patients was around 7.8%
(n = 40/456), and 9.6% (n = 44/456), respectively. Ap-
proximately 30.7% (n = 140/456) of patients had DM as
a co-morbidity (Table 1). With respect to CKD stage, a
large proportion of patients were stage 1 (28.3%), stage 2
(24.1%), and stage 3 (24.8%) CKD, whereas a small
proportion of patients were stage 4 (17.8%) and stage 5
(5%) CKD (Table 2). Among the CKD patients studied,
53.3% (243/456) had chronic MS pain.
Chronic MS pain and pain severity in different CKD stages
CKD patients were divided into three groups: early CKD
(CKD stage 1–2), CKD stage 3–4, and CKD stage 5, in
order to compare the percentage of patients with
chronic MS pain between groups. It was found that
similar prevalence of chronic MS pain was noted in early
CKD, CKD stage 3–4, and CKD stage 5 [CKD stage 1–2
vs. CKD stage 3–4 vs. CKD stage 5: 49.4% (n = 118/239)
Table 1 Baseline characteristics classified according to the presence of chronic musculoskeletal (MS) pain
All patients n = 456 No chronic MS pain n = 213 Chronic MS pain n = 243 p
Age (y) 63.3 ± 14.1 62.4 ± 14.5 64.6 ± 13.5 0.09
Male (n, %) 194 (42.5%) 64 (30.0%) 130 (53.5%) <0.001*
Body mass index (Kg/m2) 25.5 ± 3.9 25.0 ± 3.4 26.3 ± 4.3 0.001*
Waist (cm) 89.9 ± 10.9 87.8 ± 10.2 93.2 ± 11.2 0.003*
Smoking (n, %) 181 (39.7%) 89 (41.8%) 92 (37.8%) 0.754
Alcohol use (n, %) 131 (28.7%) 65 (30.5%) 66 (27.2%) 0.990
Betel nut use (n, %) 26 (5.7%) 8 (3.8%) 18 (7.4%) 0.078
NSAID use (n, %) 40 (7.8%) 16 (7.5%) 20 (8.2%) 0.854
Chinese herb use (n, %) 44 (9.6%) 22 (10.3%) 22 (9.1%) 0.822
Co-morbidity
DM (n, %) 140 (30.7%) 75 (35.2%) 65 (26.7%) 0.034*
Hypertension (n, %) 286 (62.7%) 124 (58.2%) 162 (66.7%) 0.059
CAD (n, %) 35 (7.6%) 19 (8.9%) 16 (6.5%) 0.312
PAD (n, %) 2 (0.4%) 1 (0.5%) 1 (0.4%) 0.935
CHF (n, %) 13 (2.9%) 7 (3.2%) 6 (2.4%) 0.465
Stroke (n, %) 19 (4.2%) 7 (3.2%) 12 (4.9%) 0.429
Hyperuricemia (n, %) 226 (49.6%) 54 (25.5%) 172 (71.0%) <0.001*
SLE (n, %) 2 (0.4%) 1 (0.5%) 1 (0.4%) 0.935
Urolithiasis (n, %) 15 (3.3%) 8 (3.8%) 7 (2.9%) 0.502
PKD (n, %) 1 (0.2%) 1 (0.5%) 0 (0%) 0.372
RA (n, %) 3 (0.7%) 2 (0.9%) 1 (0.4%) 0.723
Spondylarthropathies (n,%) 0 (0%) 0 (0%) 0 (0%) 1.000
Spine OA (n, %) 3 (0.7%) 0 (0%) 3 (1.2%) 0.372
Back pain (n, %) 48 (10.5%) 1 (0.5%) 48 (19.8%) <0.001*
Diuretics use (n, %) 63 (13.8%) 27 (12.7%) 36 (14.8%) 0.454
Allopurinol use (n, %) 213 (46.7%) 50 (23.5%) 163 (67.1%) <0.001*
Blood pressure
Systolic pressure (mm Hg) 133 ± 19 130 ± 18 135 ± 19 0.006*
Diastolic pressure (mm Hg) 73 ± 10 73 ± 10 74 ± 11 0.631
Notes: Values expressed as mean ± SD or percent.
Abbreviations: MS: musculoskeletal, NSAID: non-steroid anti-inflammatory drug, CKD: chronic kidney disease, DM: diabetes mellitus, CAD: coronary artery disease,
PAD: peripheral arterial disease, CHF: congestive heart failure, SLE: systemic lupus erythematosus, PKD: polycystic kidney disease, RA: rheumatoid arthritis,
OA: osteoarthritis.
*Statistical significance based on the chi-square test for categorical variables, and t test for continuous variables.
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(Figure 2).
In CKD patients with chronic MS pain, severe pain
accounted for 58% (n = 141/243) of chronic MS pain,
moderate pain about 28.4% (n = 69/243), and mild pain
only accounted for 15.6% (n = 38/243) of chronic MS pain.
Mild chronic MS pain was noted in 17.8% (n = 21/118) of
CKD patients with stage 1–2 disease, 13.3% (n = 15/113) of
CKD patients with stage 3–4 disease, and 16.7% (n = 2/12)
of CKD patients with stage 5 disease (p = 0.594). Moderate
chronic MS pain was noted in 28% (n = 33/118) of
CKD patients with stage 1–2 disease, 31.9% (n = 36/113)
of CKD patients with stage 3–4 disease, and 0% (n = 0/12)of CKD patients with stage 5 disease (p < 0.001). Severe
chronic MS pain was found in 54.2% (n = 64/118) of CKD
patients with stage 1–2 disease, 54.9% (n = 62/113) of CKD
patients with stage 3–4 disease, and 83.3% (n = 10/12) of
CKD patients with stage 5 disease (p < 0.001).
Observed differences between CKD patients with chronic
MS pain and no chronic MS pain
Compared with patients who experienced no chronic
MS pain, those who reported chronic MS pain were
more likely to be male, have a higher BMI and waist
circumference, higher systolic blood pressure, and were
less likely to have DM as a co-morbidity. In particular,
Table 2 Laboratory parameters classified according to the presence of chronic musculoskeletal (MS) pain
All patients n = 456 No chronic MS pain n = 213 Chronic MS pain n = 243 p
Serum parameters
BUN (mg/dL) 8.4 ± 3.4 8.6 ± 3.6 8.3 ± 3.1 0.019
Scr (mg/dL) 1.5 ± 1.1 1.4 ± 1.1 1. 6 ± 1.1 0.119
eGFR (mL/min/1.73 m2) 65 ± 34 68 ± 36 63 ± 31 0.107
CKD stage 0.074
1 (n, %) 129 (28.3%) 77 (36.2%) 52 (21.4%)
2 (n, %) 110 (24.1%) 44 (20.7%) 66 (27.2%)
3 (n, %) 113 (24.8%) 49 (23.0%) 64 (26.3%)
4 (n, %) 81 (17.8%) 32 (15.0%) 49 (20.2%)
5 (n, %) 23 (5.0%) 11 (5.2%) 12 (4.9%)
Haemoglobin (g/dL) 11.8 ± 2.1 11.4 ± 2.1 12.4 ± 2.1 0.010*
Albumin (g/dL) 3.9 ± 0.5 3.9 ± 0.6 3.9 ± 0.5 0.882
Ca (mg/dL) 9.2 ± 0.7 9.3 ± 0.5 9.2 ± 0.8 0.631
P (mg/dL) 3.9 ± 0.8 3.8 ± 0.7 4.0 ± 0.9 0.222
Ca × P (mg2/mL2) 32.3 ± 13.4 30.7 ± 13.5 34.1 ± 13.3 0.039*
iPTH (g/mL) 62.1 ± 55.1 62.2 ± 54.5 62.0 ± 56.0 0.964
Cholesterol (mg/dL) 193.6 ± 38.7 196.1 ± 45.8 189.3 ± 23.2 0.586
Triglycerol (mg/dL) 116.2 ± 65.6 120.3 ± 84.0 111.2 ± 35.0 0.699
Uric acid (mg/dL) 5.4 ± 2.1 5.5 ± 2.1 5.3 ± 2.1 0.294
hsCRP (mg/L) 4.6 ± 11.8 4.25 ± 13.3 4.96 ± 9.4 0.535
Notes: Values expressed as mean ± SD or percent.
Abbreviations: MS: musculoskeletal, BUN: blood urea nitrogen, eGFR: estimated glomerular filtration rate, Ca: calcium, P: phosphate, Ca × P: product of calcium and
phosphate, iPTH: intact parathyroid hormone, hs-CRP: high-sensitivity C reactive protein.
*p < 0.05 (p values are based on Student t test for analysis of continuous variables).
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and back pain co-morbidities. One hundred seventy two
patients (76.1%, 172/226) who had hyperuricemia had
chronic MS pain, but only 71 patients (30.1%, 71/230)
without hyperuricemia had chronic MS pain (p < 0.001)
(Figure 3). Higher haemoglobin levels (chronic MS painFigure 2 The percentage of chronic MS pain in CKD patients; the
percentage of mild, moderate and severe chronic MS pain in CKD
patients with chronic MS pain. Abbreviations: MS: musculoskeletal,
CKD: chronic kidney disease.vs. no chronic MS pain: 12.4 ± 2.1 vs. 11.4 ± 2.1 g/dL,
p = 0.010) and Calcium × phosphate product (chronic
MS pain vs. no chronic MS pain: 34.1 ± 13.3 vs. 30.7 ±
13.5 mg2/mL2, p = 0.039) were also linked with the
presence of chronic MS pain. Chronic MS pain was notFigure 3 The percentage of chronic MS pain was significantly
higher in patients with co-morbidity of hyperuricemia rather
than without hyperuricemia (76.1% vs. 30.1%).
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tion, or co-morbidities such as hypertension, CAD, PAD,
CHF, stroke, SLE, urolithiasis, PKD, RA, spondylarthropa-
thies, spine OA, and diuretics use. In particular, there was
no significant difference between current NSAID and
Chinese herb use in patients with and without chronic MS
pain (NSAID: 8.2% vs. 7.5%, p = 0.854; Chinese herb: 9.1%
vs. 10.3%, p = 0.822). The presence of chronic MS pain
was also not associated with renal function (BUN and Scr,
eGFR, CKD stage), albumin, Ca, P, iPTH, cholesterol,
triglycerides, uric acid, or hs-CRP.
Factors associated with chronic MS pain by binary logistic
regression analysis
In this particular study, univariate analysis indicated that
chronic MS pain was significantly associated with male
gender, higher BMI, co-morbidity of hyperuricemia and
back pain, higher systolic blood pressure, higher haemo-
globin levels, higher Calcium × phosphate product, and
less co-morbidity of DM. However, after multivariate
analysis, chronic MS pain was only positively and inde-
pendently, significantly associated with hyperuricemia
and a higher Calcium × phosphate product, whereas
male gender, BMI, co-morbidity of back pain and DM,
systolic blood pressure, and haemoglobin level lost
significance (Table 3). CKD patients were then sub-
grouped into patients with or without hyperuricemia as
co-morbidity. In CKD patients with hyperuricemia,
multivariate analysis indicated that only DM was nega-
tively associated with chronic MS pain (odds ratio:
0.413, p = 0.02), but the calcium × phosphate product
lost significance. However, in CKD patients without
hyperuricemia, multivariate analysis showed that the
calcium × phosphate product was independently and
significantly associated with chronic MS pain (odds ratio:
1.093, p = 0.027).
Discussion
The mechanisms associated with chronic MS pain in
CKD patients are multi-factorial. The present study
enrolled mostly early CKD patients, and for the first
time focused on chronic MS pain in this population.
The findings demonstrated that chronic MS pain was
independently and significantly associated with hyperuri-
cemia and the product of calcium and phosphate levels.
In CKD patients with hyperuricemia, chronic MS pain
was negatively, independently, and significantly asso-
ciated with the presence of DM. However, in CKD
patients without hyperuricemia, chronic MS pain was
positively, independently, and significantly associated
with the product of the calcium and phosphate levels.
Furthermore, CKD stage 5 patients seemed to suffer
from more severe chronic MS pain compared to other
stage CKD patients.These findings suggest that co-morbidity of hyperuri-
cemia may be one of the major co-morbidities that
contribute to chronic MS pain in CKD patients after
adjustment of other confounders. This finding may
account for the high association between hyperuricemia
and CKD [18]. Hyperuricemia could be a consequence
of impaired kidney function, diuretic therapy, or oxida-
tive stress [19]. Therefore, it is not surprising that the
co-morbidity of hyperuricemia is associated with chronic
MS pain. However, the results demonstrated that there
was no significant difference in uric acid levels between
CKD patients with and without chronic MS pain. This
finding may confirm that normal serum uric acid level at
the onset of CKD does not exclude an acute gouty attack
[20]. Adequate uric acid medical control for chronic MS
pain patients with hyperuricemia may also explain the
similar uric acid levels in the study patients with or
without chronic MS pain.
Chronic pain may be caused by various factors. This
study only focused on MS pain and excluded other
origins of chronic pain, such as neuropathic pain. The
possible sources of chronic MS pain are gout, renal bone
disease, and ischemic bone pain. The results showed that
the calcium × phosphate product levels were significantly
associated with chronic MS pain. Renal bone disease is a
common complication of CKD. Imbalance of calcium
and phosphate, vitamin D deficiency, and hyperparathyr-
oidism are considered to cause renal bone disease [21].
However, in this study, patients with chronic MS pain
had similar serum calcium, phosphate, and iPTH levels
as those patients without chronic MS pain. This suggests
that renal bone disease may not be the cause of chronic
MS pain in the CKD patients under study. The cal-
cium × phosphate product levels had been found to
correlate with vascular calcification [22]. Therefore,
vascular calcification-related micro-angiopathy and ische-
mic bone pain may explain why this product was strongly
associated with chronic MS pain, especially in patients
without hyperuricemia. Golan et al. [11] found that higher
serum calcium and iPTH levels were independently
associated with chronic pain in haemodialysis patients.
The differences in the study populations between CKD
patients pre- and post-dialysis may explain these different
findings. However, these results together suggest that
the calcium-phosphate imbalance is a crucial factor for
chronic MS pain in CKD patients.
Diabetic nephropathy is a common complication of
diabetes mellitus. In the present study, it was found that
30.7% of patients had DM as co-morbidity. This study
found that patients with chronic MS pain were less likely
to have DM than those with no chronic MS pain (26.7%
vs. 35.2%, Table 1). In multivariate analysis, it was found
that the co-morbidity of DM was negatively associated
with chronic MS pain in CKD patients with hyperuricemia
Table 3 Factors associated with chronic MS pain: univariate and multivariate analyses
Univariate 95% confidence
interval
p Multivariate 95% confidence
interval
p
Odds ratio Odds ratio
All patients
Age (y) 1.002 0.985–1.018 0.913
Male gender 2.295 1.562–3.374 <0.001
Body mass index (Kg/m2) 1.092 1.037–1.151 0.001
Co-morbidity of DM 0.908 0.603–1.368 0.644
Co-morbidity of hyperuricemia 7.167 4.655–11.034 <0.001 8.235 2.129–31.852 0.002*
Co-morbidity of back pain 85.808 11.722–628.114 <0.001
Systolic blood pressure (mmHg) 1.015 1.004–1.026 0.007
Haemoglobin (g/dL) 1.256 1.050–1.503 0.013
Ca × P (mg2/mL2) 1.226 1.044-1.520 0.010 1.028 1.008–1.131 0.022*
Patients with co-morbidity of hyperuricemia
Age (y) 0.985 0.961–1.011 0.258
Male gender 2.080 0.964–4.486 0.062
Body mass index (Kg/m2) 1.093 0.981–1.194 0.057
Co-morbidity of DM 0.481 0.235–0.981 0.044 0.413 0.196–0.815 0.020#
Co-morbidity of back pain 8.995 0.651–18.143 0.998
Systolic blood pressure (mmHg) 1.011 0.992–1.031 0.248
Haemoglobin (g/dL) 1.415 1.016–1.971 0.040
Ca × P (mg2/mL2) 0.994 0.937–1.054 0.835
Patients without co-morbidity of hyperuricemia
Age (y) 1.020 0.983–1.042 0.076
Male gender 0.958 0.548–1.676 0.881
Body mass index (Kg/m2) 1.027 0.948–1.113 0.515
Co-morbidity of DM 1.505 0.845–2.679 0.165
Co-morbidity of back pain 6.182 0.353–17.313 0.998
Systolic blood pressure (mmHg) 1.013 0.997–1.029 0.107
Haemoglobin (g/dL) 1.085 0.842–1.398 0.528
Ca × P (mg2/mL2) 1.083 1.012–1.159 0.021 1.093 1.010–1.179 0.027#
*p from logistic regression adjusted for age, male gender, body mass index, co-morbidity of diabetes, hyperuricemia, and back pain, systolic blood pressure, serum
haemoglobin, and product of calcium and phosphate levels.
#p from logistic regression adjusted for age, male gender, body mass index, co-morbidity of diabetes, and back pain, systolic blood pressure, serum haemoglobin,
and product of calcium and phosphate levels.
Abbreviations: MS, musculoskeletal; DM, diabetes mellitus, CA × P, product of calcium and phosphate.
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possible explanation is that there is a negative association
between co-morbidity of DM and hyperuricemia. How-
ever, in the present study it was found that there was no
significant association between DM and hyperuricemia.
Moreover, several studies have found high prevalence of
gout in patients with Type 2 diabetes [23,24]. Choi et al.
found that hyperuricemia is a risk factor for diabetes
mellitus [25]. Moreover, Lai et al. found that gout and type
2 diabetes mellitus shared the most common genetic
factors, which explains why there existed a mutual inter-
dependent effect on higher incidences [26]. This may also
be due to diabetic neuropathy. Previous studies haveshown that pain-inhibiting neuropathy caused by glucose
metabolism dysfunction may hide osteoarthritis pain and
delay diagnosis of osteoarthritis [27]. Moreover, silent
ischemia with less chest pain during acute coronary
syndrome was significantly higher in diabetic patients,
probably due to cardiac autonomic neuropathy [28]. Con-
sequently, it is possible that diabetic neuropathy in
diabetic CKD patients may inhibit or mask chronic MS
pain. This may explain the finding of diabetes as a pro-
tective factor from chronic MS pain in CKD patients with
hyperuricemia.
The study found that patients with chronic MS pain
had a similar prevalence of NSAIDs or Chinese herbal
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pain. In our study, there was no difference in use of
NSAIDs or Chinese herbal medication between patients
with hyperuricemia and without hyperuricemia. One
possible explanation regarding the lack of association
between NSAIDs use in CKD patients with pain may be
due to our centre’s policy to reduce the use of NSAIDs
in patients with chronic MS pain. Our CKD education
provides CKD patients with information on protecting
renal function, including better blood pressure control
and avoidance of NSAIDs and Chinese herbal medica-
tion use. There was a significantly lower rate of NSAIDs
use (7.8%) in our CKD study patients with chronic MS
pain as compared to the report of Pham et al. (23.2%)
[29]. This may be the reason why our study patients had
lower prevalence of NSAIDs use and Chinese herbal
medication. Another explanation is that CKD patients in
nephrology clinics were usually reminded of avoiding
NSAIDs agents in order to protect their kidney function.
The present study revealed that 53.3% patients had
chronic MS pain, with a mean eGFR around 65 ml/min.
However, Cohen et al. [10] reported that 69% of CKD
patients with eGFR around 33.4 mL/min experience
pain. The difference in results may be due to the defin-
ition of pain duration. The present study focused on
chronic MS pain lasting for more than 3 months.
However, Cohen et al. [10] defined pain duration on the
basis of the pain experienced by the patients in the past
month. Besides, the present study patients are 100%
Asian, whereas 74% of Cohen’s patients were Afro-
Americans. Thus, racial differences may also contribute
to the difference in prevalence of pain in CKD patients.
Nevertheless, these data provide information on the
prevalence of chronic MS pain in CKD patients.
The results of the present study indicate a correlation
between the co-morbidity of hyperuricemia, the calcium×
phosphate product levels, and the co-morbidity of DM
with chronic MS pain in CKD patients. This study raises
the importance of uric acid control and gout prevention
to decrease the possibility of chronic MS pain, thereby
improving the quality of life in CKD patients. In addition,
the study found that the calcium × phosphate product
levels were an important factor for chronic MS pain,
especially in CKD patients without hyperuricemia. Results
of this study demonstrate that the calcium× phosphate
product levels are an important laboratory parameter to
consider while treating CKD patients with chronic MS
pain and without hyperuricemia. Additionally, it was
demonstrated that NSAID or Chinese herb use was not
very common in CKD patients. Low prevalence of NSAID
and Chinese herb use (7.8% and 9.6%) may indicate either
good patient education by healthcare professionals, or an
underestimation or inaccurate reporting of NSAID and
Chinese herb use by patients.This study had several limitations. The information
regarding pain relief agents was lacking. Furthermore,
the colchicine use for gout relief in study patients was
not collected. In addition, quality of life was not evalu-
ated in this study. However, we believe that the results
provide a solid basis for studies that will further explore
these relationships. The ultimate goal should be a better
understanding and treatment of chronic MS pain in
CKD patients.
Conclusion
In summary, the present study demonstrated that chronic
MS pain was independently and significantly associated
with hyperuricemia and the calcium× phosphate product
levels. In addition, in CKD patients with hyperuricemia,
chronic MS pain was negatively, independently, and sig-
nificantly associated with DM. However, in CKD patients
without the co-morbidity of hyperuricemia, chronic MS
pain was independently and significantly associated with
the calcium× phosphate product levels.
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